Projects & Innovations

Development of nano-size nuclear emulsion production, development and production of measurement instruments for muonic x-ray analysis

JSC Compania Slavich is the only in the worldmanufacturer (after Fuji (Japan) stopped production of nuclea emulsion) of the emulsion of ПЭ-2 type with the grain of 8-13nm size (the so-called holographic emulsion)

Nano-size nuclear emulsion may be used both for R&D purposes and for the practical one too: to introduce muonic x-ray analysis, an innovative method of materials and processes control. Muonic x-ray analysis, compared to X-ray, may give more extensive information on the processes, going on in the objectunder examination. Besides, itdoesn’ trequireradiationsource.

The primary consumers of nuclear emulsion are research institutes. Its commercial potential is also estimated as very high, considering the unique nature of muonic x-ray. Its application areas range from fissile materials proliferation control, non-destructive control of VIP objects, seismic control data.

The necessary investments amount to 2mln USD.

The project is rather promising from the commercial standpoint: the nuclear emulsion global market is estimated at 100 tons a year with the price amounting to 1mln USD per ton. Potentialemulsionconsumersdemonstratetheiranticipation.

Currently, the project is in the testing phase of production: for the production of pilot shipments a special complex is installed with the capacity of up to 1kg of nano-size emulsion.

Production of packaged infusion solutions for transfusion and peritoneal dialysis

On the basis of JSC Compania Slavich it is planned to launch production of packaged infusion solutions for transfusion and peritoneal dialysis. The production facility will occupy 1000 m2. Among the key consumers will be: hospitals, clinics, polyclinics.

The price of turn-key facility building and equipment to be purchased will total 6mln euro, including:

  • Designwork280 thousand euro
  • Personneltraining, developmentofqualitycontrolsystem, preparationforlicensing– 220 thousandeuro
  • Construction and assembling – 1mln 700 thousand euro
  • Cost of the technological equipment and engineering equipment, engineering — 3 mln 800 thousand euro

Production capacity– up to 17mln plastic bottles and packages with volume arnging from 100ml to 4500ml per annum.

Currently the project is in the developmeny stage: technological components are being agreed and new medications are being registered.

Production of consumables for office appliances and printing industry, using nanotechnologies and nano materials in association with Rosnanotech

On the 1st of September 2009 Rosnanotech approved the project to launch industrial production of consumables for copy-machines, using nanotechnologies. Theprojectwillproducecartridges, tonersandphotoreceptors.

Introduction of nano-additives into the consumables will improve quality of printing and its durability, which will result in less costs for consumers.

Both components and the introduction technologies are know-how of JSC Compania Slavich and is not applied tin the full extent anywhere in the world. Now, Russia doesn’ t have its own industrial production of consumables for copy-machines and laser-jet printers, almost 100% of consumables are imported. The most modest estimates show that consumables market in Russia is as big as 1bln USD, including not only sales, but cartridge filling.

First, the project’ s products will be supplied to the domestic market, but later on they will be distributed in the neighboring states, primarily in Ukraine and Kazakhstan.

The project is totally estimated at 734.4 mln RUR. ROSNANO is going to invest about 450mln. RURintotheprojectbudget.

Implementation of the project will create the biggest national manufacturer in the industry, thus decreasing the country’ s dependence on foreign suppliers. It will also establish necessary foundation to develop in Russia xerographic printing technologies.

First products will appear in 2010. by 2013 the project will reach its design capacity. It is expected that by late 2015 the production will be estimated at 1.2bln RUR. The production will be located in Pereslavl-Zalessky (Yaroslavl region) and will require 180 new jobs.

The project is at the stage of establishing a designing company. Final talks on supplies of equipment and raw materials are held.

Production of dietary supplements in the facilities of Micron chemical plant

Chemical plant Micron will serve as a basis launch production of an efficient anti-viral immunomodulatory medication, based on protogala and probiotics/ natural nutraceuticals (as a dietary supplement), dubbed BIOFLORUM. The drug will contain live bacteria which will foster restoration, support and strengthening of intestinal microflora.

The medication will be distributed through pharmacies.

Investments into re-building of medication facility and purchasing of equipment amount to 1mln euro, and 1.2mln euro to be added for the drug promotion.


in the 1st year – 34mln RUR

in the 2nd year – 100mln RUR

in the 3rd year – 500mln RUR

The project is at the development stage. Clinical tests were completed, the medication is being registered.

Development of technologies to micronize substances

Micronizing technology will allow to change some key physical and chemical properties of substances, in particular: to speed-up suction of medicinal molecules through intestinal mucous membranes, oral and nasal cavities..

It is envisaged to locate there a pilot facility to develop the technology for substances’ micronizing.

Initially, it is planned to render to pharmaceutical companies some contractual services in terms of re-licensing generic drugs (due to new properties of substances). Further, the technology may translate into large-scale production of micronized substances upon the request of pharmaceutical companies (B2B concept)

Project cost is estimated at 1mln USD, meanwhile the study shown that the technology will be much demanded by the potential consumers, so its pay-back period will be rather small.

The project is at the development stage.